For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugates-market-and-pipeline-insight-2022.php
Table of Contents
- Impetus of Antibody Drug Conjugates
1.1 Prologue to Cancer Antibody Drug Conjugate
1.2 The ABCs of ADCs
- Structural Entities of Antibody Drug Conjugate
2.1 Rational Design of Antibody Drug Conjugates
2.1.1 Monoclonal Antibody
2.1.2 Linker
2.1.3 Drug Payload
2.2 Aspects of Conjugational Chemistry
- Revolutionizing Antibody Drug Conjugates Generation
3.1 First and Second Generation ADCs
3.2 Third Generation ADCs
- Mechanism of Cancer Antibody Drug Conjugates
4.1 Sequential Therapeutic Mechanism for Cancer
4.1.1 Selecting an Appropriate Target
4.1.2 Antigen Binding Complex
4.1.3 Antibody Drug Conjugate Internalization
4.2 Approved Antibody Drug Conjugate
- Global Cancer Antibody Drug Conjugates Market Overview
- Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
6.1 Phase
6.2 Indication
6.3 Mechanism of Action
6.4 Company
6.5 Formulation
- Global Cancer Antibody Drug Conjugates Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges
- Global Cancer Antibody Drug Conjugates Market Future Prospects
8.1 Approaching Newer Approaches
8.2 Upcoming Future Market Prospects
- Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
- Marketed Cancer Antibody Drug Conjugate Clinical Insight
10.1 Brentuximab Vedotin (Adcetris)
10.2 Mifamurtide (Junovan and Mepact)
10.3 Gemtuzumab Ozogamicin (Mylotarg)
10.4 Trastuzumab Emtansine (Kadcyla)
10.5 Ibritumomab Tiuxetan (Zevalin and Zevamab)
10.6 Satumomab (OncoScint CR/OV)
- Competitive Landscape
11.1 AbbVie
11.2 AbGenomics Corporation
11.3 Biogen Idec
11.4 Biotest
11.5 Bristol-Myers Squibb
11.6 Celldex Therapeutics Inc
11.7 Helix BioPharma
11.8 IBC Pharmaceuticals
11.9 ImmunoGen
11.10 Immunomedics
11.11 Merck
11.12 Millennium
11.13 Nordic Nanovector
11.14 Novartis
11.15 PDL BioPharma
11.16 Progenics Pharmaceuticals
11.17 Roche
11.18 Seattle Genetics
11.19 Stem CentRx
11.20 UCB
11.21 Viventia Biotechnologies
Figure 1-1: Advantages of Antibody Drug Conjugates
Figure 2-1: Detailed Structure of Antibody Drug Conjugate
Figure 2-2: Components of Antibody Drug Conjugates
Figure 2-3: Categorization of the Types of Linkers
Figure 2-4: Conjugation Strategies Adopted for Antibody Drug Conjugate
Figure 3-1: Difference Between First and Second Generation Antibody Drug Conjugate
Figure 3-2: Major Challenges of the Second Generation Antibody Drug Conjugate
Figure 4-1: Mechanism of Antibody Drug Conjugate
Figure 4-2: Mechanism of Brentuximab Vedotin
Figure 4-3: Mechanism of Trastuzumab Emtansine
Figure 5-1: Global – Antibody Drug Conjugates Market (US$ Billion), 2014-2022
Figure 5-2:Global – Adcetris Sales (Million US$), 2016-2022
Figure 5-3: Global – Kadcyla Sales (Million US$), 2016-2022
Figure 5-4: Global – Kadcyla Sales by Region (%), 2016
Figure 6-1: Global – Cancer Antibody Drug Conjugates Pipeline By Phase (%), 2017 till 2022
Figure 6-2: Global – Cancer Antibody Drug Conjugates Pipeline By Phase (Number), 2017 till 2022
Figure 6-3: Global – Cancer Antibody Drug Conjugates Pipeline By Indication (Number), 2017 till 2022
Figure 6-4: Global – Cancer Antibody Drug Conjugates Pipeline By Mode of Action (Number), 2017 till 2022
Figure 6-5: Global – Cancer Antibody Drug Conjugates Pipeline By Company (Number), 2017 till 2022
Figure 6-6: Global – Cancer Antibody Drug Conjugates Pipeline By Formulation (Number), 2017 till 2022
Figure 7-1: Antibody Drug Conjugates Market Favorable Parameters
Figure 7-2: Major Challenges Faced by Antibody Drug Conjugate Market
Figure 11-1:AbGenomics – Clinical Pipeline
Figure 11-2: Celldex – Clinical Pipeline
Figure 11-3: Merck – Clinical Pipeline
Figure 11-4: Millennium – Clinical Pipeline
Figure 11-5: Novartis – Clinical Pipeline
Figure 11-6: Progenics – Clinical Pipeline
Figure 11-7: Roche – Clinical Pipeline
Figure 11-8: Seattle Genetics – Clinical Pipeline
Figure 11-9: Viventia – Clinical Pipepline
Table 4-1: FDA Approved Antibody Drug Conjugate For Cancer
Table 4-2: Some of the Antibody Drug Conjugates under Development
Table 5-1: Drugs for Treatment of HER2-Positive Breast Cancer